| Title |
|
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
idiopathic pulmonary fibrosis |
|
|
interstitial lung disease |
|
|
progressive pulmonary fibrosis |
|
|
| Type of document |
|
| OrcId |
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
| DOI |
|
| Abstract |
|
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis. |
|
|
| Link |
|
| Citation |
|
Respirology (Carlton, Vic.) 2024-02; 29(2) |
|
|
| Jornal Title |
|
Respirology (Carlton, Vic.) |
|
|
| ISSN |
|